Pregled bibliografske jedinice broj: 1222723
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors // Knjiga sažetaka FIP World Congress of Pharmacy and Pharmaceutical Sciences 2022, International Pharmaceutical Federation, 2022
Sevilla: International Pharmaceutical Federation (FIP), 2022. 394, 1 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1222723 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Venous thromboembolism risk in patients with
hormone receptor-positive HER2-negative metastatic
breast cancer treated with CDK4/6 inhibitors
Autori
Baković, Matea ; Ortner Hadžiabdić, Maja ; Silovski, Tajana ; Sertić, Miranda
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Knjiga sažetaka FIP World Congress of Pharmacy and Pharmaceutical Sciences 2022, International Pharmaceutical Federation, 2022
/ - Sevilla : International Pharmaceutical Federation (FIP), 2022
Skup
80th FIP World Congress of Pharmacy and Pharmaceutical Sciences (FIP Seville 2022)
Mjesto i datum
Sevilla, Španjolska, 18.09.2022. - 22.09.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Venous thromboembolism ; HR+/HER2- breast cancer ; CDK4/6 inhibitors
Sažetak
Analysis of venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer, who are treated with CDK4/6 inhibitors
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Projekti:
UIP-2019-04-8461 - Nova bioanalitička rješenja za personalizaciju terapije raka dojke (OncoBioAnalytics) (Sertić, Miranda, HRZZ - 2019-04) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Klinički bolnički centar Zagreb
